CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM069085
Első szerző:Amin, N. B.
Cím:Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes / Amin N. B., Aggarwal N., Pall D., Paragh G., Denney W. S., Le V., Riggs M., Calle R. A.
Dátum:2015
ISSN:1462-8902
Megjegyzések:AIM:To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM).METHODS:Patients were randomized to once-daily PF-04937319 doses of 10, 50, 100?mg, or matching placebo (Study B1621002); or PF-04937319 doses of 3, 20, 50, 100?mg, or matching placebo (Study B1621007). Titrated glimepiride (Study B1621002) or sitagliptin (Study B1621007) were included in a double-dummy manner. The primary measure was change from baseline in glycated haemoglobin (HbA1c) at week 12. Key secondary measures included other glycaemic variables and safety and tolerability.RESULTS:In the 639 patients randomized, the minimally efficacious PF-04937319 dose was identified as 50?mg once daily. At the highest PF-04937319 dose tested (100?mg), on average, a clinically significant reduction in HbA1c [-4.94 or -5.11?mmol/mol (-0.45 or -0.47%), placebo-adjusted], which was similar to that achieved with sitagliptin [-4.69?mmol/mol (-0.43%)] but lower than that achieved with titrated glimepiride [-9.07?mmol/mol (-0.83%)], was observed. At this dose, the effect on fasting plasma glucose was not consistent between the two studies (Study B1621002 vs Study B1621007: placebo-adjusted mean change of -0.83 vs +0.50?mmol/l). PF-04937319 was well tolerated at doses up to 100?mg. Hypoglycaemia was reported in 2.5% of patients (on placebo), 5.1% of patients (on PF-04937319 100?mg), 1.8% of patients (on sitagliptin) and 34.4% of patients (on titrated glimepiride).CONCLUSIONS:In patients on metformin monotherapy, the addition of a 100-mg dose of PF-04937319 improved glycaemic control and was well tolerated.TRIAL REGISTRATION:ClinicalTrials.gov NCT01475461 NCT01517373.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
PF-04937319
glycaemic control
type 2 diabetes
Megjelenés:Diabetes Obesity & Metabolism 17 : 8 (2015), p. 751-759. -
További szerzők:Aggarwal, N. Páll Dénes (1967-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Denney, W. S. Le, V. Riggs, M. Calle, R. A.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM015579
Első szerző:Balogh Zoltán (belgyógyász, gasztroenterológus, diabetológus)
Cím:Gemfibrozil increases paraoxonase activity in type 2 diabetic patients : a new hypothesis of beneficial action of fibrates? / Balogh Z., Seres I., Harangi M., Kovács P., Kakuk G., Paragh G.
Dátum:2001
ISSN:1262-3636
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Diabetes & Metabolism 27 : 5Pt1 (2001), p. 604-610. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Kakuk György (1938-2018) (belgyógyász) Paragh György (1953-) (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM017806
Első szerző:Kalmár Tímea
Cím:Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus / Kalmár T., Seres I., Balogh Z., Káplár M., Winkler G., Paragh Gy.
Dátum:2005
Megjegyzések:In type 2 diabetes mellitus the decreased catabolism of triglyceride-rich lipoproteins as a consequence of mainly the decreased lipoprotein lipase activity results in hypertriglyceridaemia and other lipoprotein alterations promoting atherosclerosis. The high-density lipoprotein-associated enzyme, paraoxonase, prevents the oxidation of low-density lipoprotein, which is an antiatherogenic effect. AIM: to examine the relation between the activities of enzymes influencing HDL remodelling- LPL and PON- in type 2 diabetes mellitus. METHODS: 56 newly diagnosed type 2 diabetic patients and 39 healthy controls were involved in the study. The serum PON activity was measured spectrophotometrically using paraoxone as substrate. PON phenotype was determined by the dual substrate method, PON mass was measured by ELISA. The determination of lipoprotein lipase activity was performed using 3H-triolein. RESULTS: We noticed smaller PON activity decrease in our newly diagnosed diabetic subjects compared to the previous studies which investigated the alteration of enzyme activity after a longer duration of diabetes mellitus. The lipoprotein lipase activity showed a positive correlation with PON activity (r=0.43; P<0.02). Interestingly, the PON activity of the homozygous-low activity group did not correlate with the LPL activity, while in the heterozygous and homozygous-high activity groups there was a significantly positive correlation (r=0.51; P<0.05) between PON and LPL activity. CONCLUSION: Besides lipid alterations, the metabolic changes of type 2 diabetes mellitus influence the reduction of the antioxidant capacity of HDL by remodelling HDL and decreasing PON activity via modification of lipoprotein lipase activity, which might contribute to accelerated atherosclerosis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Diabetes Metabolism. - 31 : 6 (2005), p. 574-580. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Balogh Zoltán (1965-) (belgyógyász, gasztroenterológus, diabetológus) Káplár Miklós (1965-) (belgyógyász, diabetológus) Winkler Gábor Paragh György (1953-) (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM042196
Első szerző:Lukács Andrea (oktató)
Cím:Health-related quality of life of youths with type 1 diabetes : reliability and validity of the Hungarian version of the PedsQL 3.0 diabetes module / Andrea Lukács, Beatrix Varga, Szabolcs Barótfi, Emőke Kiss-Tóth, László Barkai
Dátum:2012
Megjegyzések:Background: In the routine care of diabetes, mostly the clinical parameters are controlled and little attention is paid to the quality of life assessment. A questionnaire must be culturally adapted in the country where it is intended to be used. The aim of the study was to assess health-related quality of life in youths with type 1 diabetes using the PedsQL 3.0 Diabetes Module and to evaluate the psychometric properties in patient and control subjects. Methods: Diabetes and Generic Module were administered to 355 youths with type 1 diabetes (8-18 y/o) and their parents. Generic Module was completed by 294 age-matched control participants and their parents. Feasibility, internal consistency reliability, reproducibility, convergent, discriminant and concurrent validities were evaluated. Results: Minimal floor and moderate ceiling effects and hardly any missing item responses proved the feasibility. Cronbach's ? was gretaer than 0.70 in all subscales and met the criterion of 0.90 in total-items reliability. Testretest reliability was demonstrated with Pearson coefficients. We found good agreement between the children's and parents's answers, although parents underestimated their diabetic children in all subscales. The instrument was able to differentiate between the health-related quality of life of optimal, suboptimal and high risk metabolic control. The Diabetes Modul subscales and the Generic Module total scale correlated well, except the worry subscale. Conclusions: Diabetic youths had similar health-related quality of life as their non-diabetic peers. Parents underestimated their diabetic child's quality of life, but this was not the case in the healthy population. Both diabetic and healthy boys had better perception of quality of life than girls. The nationally adapted version of the Pediatric Quality of Life Inventory 3.0 Diabetes Module designed for children and adolescents was reliable and valid instrument for assessing health-related quality of life in youths with type 1 diabetes.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Diabetes & Metabolism. - 3 : 4 (2012), p. 1000191. -
További szerzők:Varga Beatrix Barótfi Szabolcs Kiss-Tóth Emőke Barkai László (1958-) (gyermekgyógyász)
Pályázati támogatás:TÁMOP-4.2.1.B-10/2/KONV-2010-0001
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM031513
Első szerző:Nowicki, M.
Cím:Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment / Nowicki, M., Rychlik, I., Haller, H., Warren, M. L., Suchower, L., Gause-Nilsson, I., for the D1680C00007 Investigators
Dátum:2011
ISSN:1462-8902
Megjegyzések:AIM: To evaluate the efficacy and safety of saxagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) and renal impairment.METHODS: In this multicentre, randomized, parallel-group, double-blind, placebo-controlled study, patients with glycated haemoglobin (HbA1c) 7-11% and creatinine clearance <50 ml/min were stratified by baseline renal impairment (moderate, severe or end-stage on haemodialysis), and randomized (1 : 1) to saxagliptin 2.5 mg once daily or placebo for 12 weeks. Oral antihyperglycaemic drugs and insulin therapy present at enrolment were continued throughout the study. The absolute change in HbA1c from baseline to week 12 (primary efficacy end-point) was analysed using an analysis of covariance model with last observation carried forward methodology.RESULTS: A total of 170 patients were randomized and treated. The adjusted mean decrease from baseline to week 12 in HbA1c was statistically significantly greater in the saxagliptin group than in the placebo group; the difference between treatments was -0.42% (95% confidence interval: -0.71 to -0.12%, p = 0.007). Adjusted mean HbA1c decreases from baseline to week 12 were numerically greater with saxagliptin than with placebo in the subgroups of patients with moderate (-0.64 vs. -0.05%) and severe (-0.95 vs. -0.50%) renal impairment. HbA1c reductions were similar between saxagliptin and placebo in the subgroup with end-stage renal disease on haemodialysis (-0.84 vs. -0.87%). Saxagliptin was generally well tolerated; incidences of adverse events and hypoglycaemic events were similar to placebo.CONCLUSIONS: Saxagliptin 2.5 mg once daily is a well-tolerated treatment option for patients with inadequately controlled T2DM and renal impairment.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Diabetes Obesity & Metabolism. - 13 : 6 (2011), p. 523-532. -
További szerzők:Rychlik, I. Haller, Herman Warren, M. L. Suchower, L. Gause-Nilsson, I. Mátyus János (1957-) (belgyógyász, nephrológus) for the D1680C00007 Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM013938
Első szerző:Paragh György (belgyógyász)
Cím:The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease / Paragh G., Seres I., Harangi M., Balogh Z., Illyés L., Boda J., Szilvássy Z., Kovács P.
Dátum:2003
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Diabetes & metabolism 29 : 6 (2003), p. 613-618. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Balogh Zoltán (1965-) (belgyógyász, gasztroenterológus, diabetológus) Illyés László Boda J. Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
elektronikus változat
Borító:

7.

001-es BibID:BIBFORM073187
035-os BibID:(WoS)000425013600005 (Scopus)85030632365
Első szerző:Rosenstock, Julio
Cím:Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) / Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring, Steven G. Terra
Dátum:2018
ISSN:1462-8902
Megjegyzések:Introduction: We evaluated efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0?10.5%) on metforminmonotherapy (?1500 mg/day for ?8 weeks).Methods: Double-blind, 26-week, multicentre study with ongoing 78-week extension; 621participants randomized 1:1:1 to placebo, ertugliflozin 5 or 15 mg/day. Primary endpoint:change from baseline in HbA1c at week 26. Secondary efficacy endpoints: change frombaseline at week 26 in fasting plasma glucose (FPG), body weight, systolic/diastolic bloodpressure (SBP/DBP); participants with HbA1c <7.0% (53 mmol/mol). Pre-specified adverseevents (AEs) of special interest and percent change from baseline in bone mineral density(BMD) were also assessed at week 26.Results: At week 26, the placebo-adjusted least-squares mean change from baselineHbA1c (8.1%) was ?0.7% and ?0.9% for ertugliflozin 5 and 15 mg, respectively (both P <0.001), to final means of 7.3% and 7.2%, respectively. The odds of HbA1c <7.0% weresignificantly greater in both ertugliflozin groups vs placebo. Ertugliflozin significantly reducedFPG, body weight, SBP and DBP vs placebo. Incidence of genital mycotic infections wasincreased in ertugliflozin groups (females: placebo, 0.9%; ertugliflozin 5 mg, 5.5%; 15 mg,6.3% [P = 0.032]; males: 0; 3.1%; 3.2%), as was incidence of urinary tract infections andsymptomatic hypoglycaemia. Incidence of hypovolaemia AEs was similar across groups.Ertugliflozin had no adverse impact on BMD at week 26.Conclusions: Ertugliflozin added to metformin in inadequately controlled T2DM improvedglycaemic control, reduced body weight and BP, but increased genital mycotic infections.ClinicalTrials.gov identifier: NCT02033889.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
bone mineral density
ertugliflozin
SGLT2 inhibitor
type 2 diabetes mellitus
Megjelenés:Diabetes Obesity & Metabolism. - 20 : 3 (2018), p. 520-529. -
További szerzők:Frias, Juan Páll Dénes (1967-) (belgyógyász, kardiológus) Charbonnel, Bernard Pascu, Raluca Saur, Didier Darekar, Amanda Huyck, Susan Shi, Harry Lauring, Brett Terra, Steven G.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM106673
035-os BibID:(scopus)85143748101 (cikkazonosító)e390
Első szerző:Taybani Zoltán
Cím:One-year safety and efficacy results of insulin treatment simplification with in type 2 diabetes / Taybani Zoltán J., Bótyik Balázs, Gyimesi András, Katkó Mónika, Várkonyi Tamás
Dátum:2022
ISSN:2398-9238
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Endocrinology, Diabetes & Metabolism. - 6 : 1 (2022), p. 1-7. -
További szerzők:Bótyik Balázs Gyimesi András Katkó Mónika (1980-) (biológus) Várkonyi Tamás
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.